New therapy targets for metastatic prostate cancer
Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer
This project will use multi-omics sequencing and patient tumor models to try to find new drug targets for men with metastatic or castration-resistant prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT05577689 on ClinicalTrials.gov |
What this trial studies
Researchers will collect tumor tissue from men with metastatic prostate cancer and perform multi-omics sequencing to map genetic, transcriptomic, and other molecular features. Selected molecular candidates will be tested in patient-derived organoids and animal models to see which changes drive metastasis or drug resistance. The organoid and animal platforms are intended to link molecular findings to functional evidence that a target might be druggable. Findings will be used to build a translational research system aimed at identifying interventions for mCRPC.
Who should consider this trial
Good fit: Ideal candidates are men with histologically confirmed metastatic prostate cancer who can undergo surgery or biopsy and can provide informed consent.
Not a fit: Patients without prostate cancer, those who cannot provide an accessible tissue sample or cannot give informed consent, and men with only localized disease are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify new drug targets that lead to more effective treatments for men with metastatic castration-resistant prostate cancer.
How similar studies have performed: Previous multi-omics efforts and organoid models have shown promise in identifying candidate targets and mechanisms, but translation to new approved therapies has been limited to date.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed prostate cancer 2. metastatic disease confirmed by image examination 3. Patients who can undergo surgery or biopsy for prostate cancer 4. Able to provide informed consent Exclusion Criteria: 1. Patients diagnosed with other types of cancer besides prostate cancer 2. Not accessible to surgery sample 3. Patients fail to provide informed consent 4. Other situation that researchers think are unsuitable for this study
Where this trial is running
Shanghai, Shanghai Municipality
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Yao Zhu
- Email: mailzhuyao@163.com
- Phone: +86 15001818005
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.